AstraZeneca Announced Its Alexion Unit Completed Purchase And Licence Agreement For Early-stage Rare Disease Gene Therapy Portfolio From Pfizer For Up To $1B, Plus Tiered Royalties On Sales
Portfolio Pulse from Charles Gross
AstraZeneca's Alexion unit has completed the purchase and license agreement for an early-stage rare disease gene therapy portfolio from Pfizer. The deal is worth up to $1 billion, plus tiered royalties on sales.
September 20, 2023 | 8:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's acquisition of Pfizer's gene therapy portfolio could potentially boost its future revenues and strengthen its position in the rare disease market.
The acquisition of Pfizer's gene therapy portfolio by AstraZeneca's Alexion unit could potentially lead to the development of new treatments for rare diseases, which could boost AstraZeneca's future revenues and strengthen its position in the rare disease market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Pfizer's sale of its gene therapy portfolio to AstraZeneca could result in a short-term cash influx but may limit its future potential in the rare disease market.
While the sale of its gene therapy portfolio to AstraZeneca could result in a short-term cash influx for Pfizer, it may limit the company's future potential in the rare disease market.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100